Keywords: cheisi, farmaceutici, brexidol, chiesi, granted, exclusive, rights
Cheisi farmaceutici: Brexidol
Article | 15 May 1995
- Chiesi Farmaceutici has granted exclusive rights in Canada to Jouveinal for its non-steroidal anti-inflammatory drug Brexidol (piroxicam-beta-cyclodextran) for "a cash ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
